Skip to content
Biodatica
Start free

Janssen Research & Development, LLC

Iowa City, Iowa

OncologyFiled/ApprovedListed · JNJ

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Filed/Approved trial registered: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

1w agoTrial registeredJul 6, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Jun 13, 2025

    Metastatic Non-Small Cell Lung Cancer · APPROVED_FOR_MARKETING · sponsor: Janssen Research & Development, LLC · Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

    ClinicalTrials.gov · NCT04599712 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Feb 3, 2025

    Crohn Disease · NO_LONGER_AVAILABLE · sponsor: Janssen Research & Development, LLC · An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease

    ClinicalTrials.gov · NCT03362736 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Dec 30, 2024

    Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Solid Tumor, Adult, Prostatic Neoplasms, Castration-Resistant · ENROLLING_BY_INVITATION · sponsor: Janssen Research & Development, LLC · A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

    ClinicalTrials.gov · NCT06788509 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Nov 6, 2023

    Relapsed or Refractory B Cell Non-Hodgkin Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

    ClinicalTrials.gov · NCT05784441 (opens the source filing in a new tab)

  5. Trial

    PHASE3 registered

    Aug 30, 2022

    Arthritis, Juvenile · ACTIVE_NOT_RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

    ClinicalTrials.gov · NCT05083182 (opens the source filing in a new tab)

  6. Trial

    PHASE4 registered

    Mar 9, 2022

    Multiple Myeloma · RECRUITING · sponsor: Janssen Research & Development, LLC · A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

    ClinicalTrials.gov · NCT05201781 (opens the source filing in a new tab)

  7. Trial

    PHASE4 registered

    Dec 18, 2019

    Waldenstrom Macroglobulinemia · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

    ClinicalTrials.gov · NCT04042376 (opens the source filing in a new tab)

  8. Trial

    PHASE1 registered

    Dec 18, 2019

    Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants

    ClinicalTrials.gov · NCT04208061 (opens the source filing in a new tab)

  9. Trial

    PHASE1 registered

    Nov 29, 2019

    Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants

    ClinicalTrials.gov · NCT04030533 (opens the source filing in a new tab)

  10. Trial

    PHASE1 registered

    Oct 30, 2019

    Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

    ClinicalTrials.gov · NCT04147338 (opens the source filing in a new tab)

  11. Trial

    PHASE1 registered

    Sep 16, 2019

    Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of Bedaquiline 100 Milligram (mg) Tablets Administered as Different Test Formulations Compared to the Commercial Tablet Formulation (F001) in Healthy Adult Participants

    ClinicalTrials.gov · NCT04087759 (opens the source filing in a new tab)

  12. Trial

    PHASE1 registered

    Feb 13, 2019

    Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study to Assess the Drug-Drug Interaction Between Bedaquiline and Clarithromycin in Healthy Adult Participants

    ClinicalTrials.gov · NCT03800550 (opens the source filing in a new tab)

  13. Trial

    PHASE1 registered

    Dec 20, 2018

    Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study to Investigate the Different Modes of (S) Ketamine Administration in Healthy Participants

    ClinicalTrials.gov · NCT03808259 (opens the source filing in a new tab)

  14. Trial

    PHASE1 registered

    Oct 16, 2017

    Pre-Symptomatic Type 1 Diabetes · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes

    ClinicalTrials.gov · NCT03298542 (opens the source filing in a new tab)

  15. Trial

    PHASE1 registered

    Sep 26, 2017

    Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants

    ClinicalTrials.gov · NCT03298906 (opens the source filing in a new tab)

  16. Trial

    PHASE1 registered

    Nov 10, 2016

    Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants

    ClinicalTrials.gov · NCT02945020 (opens the source filing in a new tab)

  17. Trial

    Study registered

    Oct 26, 2016

    Depressive Disorder, Major · COMPLETED · sponsor: Janssen Research & Development, LLC · Study to Evaluate the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Participants With Major Depressive Disorder (MDD)

    ClinicalTrials.gov · NCT03014544 (opens the source filing in a new tab)

  18. Trial

    PHASE1 registered

    Aug 9, 2016

    Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly Japanese, and Healthy Younger Adult Japanese Subjects

    ClinicalTrials.gov · NCT02857777 (opens the source filing in a new tab)

  19. Trial

    PHASE2 registered

    Jun 27, 2012

    Major Depressive Disorder · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression

    ClinicalTrials.gov · NCT01640080 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources